Journey Medical Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$82.6Mnext fiscal year
FY EPS (est.)
$0.07next fiscal year
Monitoring Framework
Key Performance Indicators
Emrosi Net Revenue Quarterly6.3MTarget: Continued sequential and year-over-year growth to establish Emrosi as flagship product
Emrosi Total Prescriptions (TRx) Quarterly30KTarget: Exceeding 126,000 annualized run rate
Payer Coverage (U.S. Commercial Lives) Quarterly0.9Target: Maintain or expand beyond 85% of U.S. commercial lives
Adjusted EBITDA Quarterly600KTarget: Maintain positive Adjusted EBITDA for the remainder of 2026 and beyond
Watch Items
- Generic Competition on Accutane FranchiseTrigger: Further steep declines in Accutane product revenue (declined by $6.5 million in FY2025)Action: Accelerate Emrosi commercialization and optimize sales force allocation to higher-margin products
- Going Concern Explanatory ParagraphTrigger: Auditor's continued inclusion of substantial doubt about ability to continue as a going concern in SEC filingsAction: Monitor cash runway, leverage positive operating cash flow ($2.9 million in Q1 2026), and utilize the ATM sales agreement selectively to avoid excessive dilution
- New Product LaunchesTrigger: Launch of up to two new dermatology products by late 2026Action: Track regulatory milestones, commercial supply agreements, and initial sales force training schedules
Research as of 20 Jun 2026